Roxana Moslehi

From Wikipedia, the free encyclopedia

Roxana Moslehi, Ph.D. is a genetic epidemiologist. Most of her research is dedicated to the study of cancer and cancer precursors. Born in Iran and raised in Canada, she is currently an assistant professor in Epidemiology and Statistics at the State University of New York (SUNY).

Contents

[edit] Education

Roxana received her B.Sc. with honors, M.Sc. and Ph.D. degrees from the University of British Columbia (UBC) in Vancouver, Canada. Following her Ph.D., she completed a postdoctoral fellowship at the National Institutes of Health (NIH), Division of Cancer Epidemiology and Genetics (DCEG) under the supervision of Dr. Mitchell Gail. While being a postdoctoral fellow at NIH, she also received an adjunct assistant professor position at George Washington University (GWU), where she taught a course with Dr. Paul Levin.

[edit] Research

Working with Steven Narod and J.M. Friedman, she was first to estimate the penetrance of BRCA1 and BRCA2 mutations for breast, ovarian and other cancers in a study of Jewish women with ovarian cancer,[1] now the most studied hereditary cancer predisposing genes in the human genome. She also made significant contributions in the research of various other cancer risk modifying factors,[2] including involvement of NAT genes in colorectal adenomas and infectious pathogen Chlamydia psittaci in Ocular Non-Hodgkin Lymphoma[3].

[edit] Awards

Roxana Moslehi is a recipient of multiple awards and honors, including the Award for Excellence in Teaching (UBC), a Biovision Fellowship from Académie des Sciences (France) and two Awards for Research Excellence from the NIH.

[edit] Trivia

In addition to her scientific career she has also done professional runway modeling for fashion shows.

[edit] References

  1. ^ BRCA1 and BRCA2 Mutation Analysis of 208 Ashkenazi Jewish Women with Ovarian Cancer[[1]]
  2. ^ Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group.[[2]]
  3. ^ Rapidly Increasing Incidence of Ocular Non-Hodgkin Lymphoma [[3][4]]